These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34786435)

  • 1. Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones.
    Uchiyama T; Takahashi S; Nakabayashi K; Okamura K; Edasawa K; Yamada M; Watanabe N; Mochizuki E; Yasuda T; Miura A; Kato M; Tomizawa D; Otsu M; Ariga T; Onodera M
    Mol Ther Methods Clin Dev; 2021 Dec; 23():424-433. PubMed ID: 34786435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene delivery using AAV8
    Carbonaro-Sarracino DA; Chun K; Clark DN; Kaufman ML; Jin X; Wang X; Kohn DB
    Mol Ther Methods Clin Dev; 2021 Mar; 20():765-778. PubMed ID: 33738330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.
    Carbonaro DA; Jin X; Wang X; Yu XJ; Rozengurt N; Kaufman ML; Wang X; Gjertson D; Zhou Y; Blackburn MR; Kohn DB
    Blood; 2012 Nov; 120(18):3677-87. PubMed ID: 22833548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
    Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
    Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells.
    Bordignon C; Yu SF; Smith CA; Hantzopoulos P; Ungers GE; Keever CA; O'Reilly RJ; Gilboa E
    Proc Natl Acad Sci U S A; 1989 Sep; 86(17):6748-52. PubMed ID: 2549545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy.
    Igarashi Y; Uchiyama T; Minegishi T; Takahashi S; Watanabe N; Kawai T; Yamada M; Ariga T; Onodera M
    Mol Ther Methods Clin Dev; 2017 Sep; 6():8-16. PubMed ID: 28626778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
    Ferrua F; Brigida I; Aiuti A
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.
    Carbonaro DA; Jin X; Cotoi D; Mi T; Yu XJ; Skelton DC; Dorey F; Kellems RE; Blackburn MR; Kohn DB
    Blood; 2008 Jun; 111(12):5745-54. PubMed ID: 18356486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow gene therapy for adenosine deaminase deficiency.
    Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
    Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.
    Carbonaro Sarracino D; Tarantal AF; Lee CC; Martinez M; Jin X; Wang X; Hardee CL; Geiger S; Kahl CA; Kohn DB
    Mol Ther; 2014 Oct; 22(10):1803-16. PubMed ID: 24925206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y; Ariga T; Ohtsu M
    Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells.
    Cournoyer D; Scarpa M; Mitani K; Moore KA; Markowitz D; Bank A; Belmont JW; Caskey CT
    Hum Gene Ther; 1991; 2(3):203-13. PubMed ID: 1751590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.